Effect of Hyperthermic Intraperitoneal Perfusion Chemotherapy Combined with Radical Surgery and Capecitabine on Stage III Gallbladder Cancer

Sulai Liu, Zhendong Zhong, Weimin Yi, Zhangtao Yu, Zhihua Zhang, Guoyi Xia, Bo Jiang, Yinghui Song, Chuang Peng, Sulai Liu, Zhendong Zhong, Weimin Yi, Zhangtao Yu, Zhihua Zhang, Guoyi Xia, Bo Jiang, Yinghui Song, Chuang Peng

Abstract

Purpose: The aim of the study was to investigate the effect of hyperthermic intraperitoneal perfusion chemotherapy (HIPEC) combined with radical surgery and capecitabine on stage III gallbladder cancer.

Method: Seventy-eight patients with stage III gallbladder cancer treated in our hospital between December 2015 and April 2019 were retrospectively enrolled. Depending on the treatment approach, the patients were divided into the control group (radical surgery and capecitabine) and the HIPEC group (hyperthermic intraperitoneal perfusion chemotherapy combined with radical surgery and capecitabine). The patients were followed up by outpatient or through telephone until April 1, 2020. SPSS 19.0 software was applied for data analysis. Survival analysis was performed using the Kaplan-Meier method and parallel log-rank test.

Results: There were 43 cases in the control group and 35 cases in the HIPEC group. There were no significant differences in operation time, lymph node metastasis, microvascular infiltration, and nerve invasion; there was no significant difference in postoperative complications between the two groups (P > 0.05). The average hospitalization time of the HIPEC group was 23.0 ± 6.9 days, which was longer than the 20.0 ± 5.8 days of the control group (P < 0.05). The body temperatures of HIPEC group patients at 0 h and 6 h after operation were higher than those of patients in the control group (P < 0.05); however, the body temperature of the two groups gradually became the same at 12-24 h after operation. There was no liver and kidney damage in the two groups after surgery. The platelets in the HIPEC group were less than those in the control group (P < 0.05). The median survival time of HIPEC was 19.2 months, which was longer than 15.3 months in the control group. The 1-year survival rates of the two groups were 91.43% vs. 76.71%, and the 2-year survival rates were 26.29% vs. 17.53%, respectively (P < 0.05).

Conclusion: HIPEC combined with radical surgery and capecitabine for stage III gallbladder cancer can effectively prolong survival time without increasing surgery-related complications.

Conflict of interest statement

The authors declare no conflicts of interest.

Copyright © 2021 Sulai Liu et al.

Figures

Figure 1
Figure 1
Changes in body temperature of the two groups of patients: temperature measurements at 0 h and 6 h after the operation showed that the body temperature of the HIPEC group was higher than that of the control group (P < 0.05). There was no difference in body temperature between the two groups at 12, 18, and 24 hours after operation (P > 0.05).
Figure 2
Figure 2
Cumulative survival of patients with control group patients and HIPEC group patients was determined by the Kaplan–Meier method. The median survival of the surgery combined with the gemcitabine treatment group in this study was 15.3 months. And the median survival time of patients treated with HIPEC was 19.2 months (P=0.037).

References

    1. Benson A. B., D’angelica M. I., Abbott D. E., et al. NCCN guidelines insights: hepatobiliary cancers, version 1.2017. Journal of the National Comprehensive Cancer Network . 2017;15(5):563–573. doi: 10.6004/jnccn.2017.0059.
    1. Wernberg J. A., Lucarelli D. D. Gallbladder cancer. Surgical Clinics of North America . 2014;94(2):343–360. doi: 10.1016/j.suc.2014.01.009.
    1. Wu Y., Pan M., Cui S., Ba M., Chen Z., Ruan Q. Efficacy and safety of ultrasound-guided continuous hyperthermic intraperitoneal perfusion chemotherapy for the treatment of malignant ascites: a midterm study of 36 patients. OncoTargets and therapy . 2016;9:403–407. doi: 10.2147/OTT.S85564.
    1. Leigh N. L., Solomon D., Feingold D., et al. Staging gallbladder cancer with lymphadenectomy: the practical application of new AHPBA and AJCC guidelines. International Hepato-Pancreato-Biliary Association . 2019;21(11):1563–1569. doi: 10.1016/j.hpb.2019.03.372.
    1. Helderman R. F. C. P. A., Löke D. R., Verhoeff J., et al. The temperature-dependent effectiveness of platinum-based drugs mitomycin-C and 5-FU during hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer cell lines. Cell . 2020;9(8) doi: 10.3390/cells9081775.
    1. Wang W.-Y., Wu M.-F., Wu D.-B., et al. Calculating the dose of cisplatin that is actually utilized in hyperthermic intraperitoneal chemotherapy among ovarian cancer patients. Journal of Ovarian Research . 2021;14(1):p. 9. doi: 10.1186/s13048-021-00764-6.
    1. Ye J., Chen L., Zuo J., et al. A precise temperature control during hyperthermic intraperitoneal chemotherapy promises an early return of bowel function. Cancer Biology & Therapy . 2020;21(8):726–732. doi: 10.1080/15384047.2020.1775444.
    1. Primrose J. N., Fox R. P., Palmer D. H., et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. The Lancet Oncology . 2019;20(5):663–673. doi: 10.1016/s1470-2045(18)30915-x.
    1. Lin Y.-X., Jia Q.-B., Fu Y.-Y., Cheng N.-S. Mixed adenoneuroendocrine carcinoma of the gallbladder. Journal of Gastrointestinal Surgery . 2018;22(8):1452–1454. doi: 10.1007/s11605-017-3664-y.
    1. Siebenhüner A. R., Seifert H., Bachmann H., et al. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: a prospective single center phase II study. BMC Cancer . 2018;18(1):p. 72. doi: 10.1186/s12885-017-3967-0.
    1. Randle R. W., Levine E. A., Clark C. J., Stewart J. H., Shen P., Votanopoulos K. I. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for gallbladder cancer: a retrospective review. The American Surgeon . 2014;80(7):710–713. doi: 10.1177/000313481408000728.
    1. Kyriazanos I., Kopanakis N., Kalles V., et al. Hepatobiliary and pancreatic procedures during cytoreductive surgery and HIPEC. Journal of B. U. ON.: Official Journal of the Balkan Union of Oncology . 2017;22(5):1338–1344.
    1. Zhu X., Zhang X., Hu X., et al. Survival analysis of patients with primary gallbladder cancer from 2010 to 2015. Medicine . 2020;99(40) doi: 10.1097/md.0000000000022292.e22292
    1. Yao Z., You C., He M. Effect and feasibility of therapeutic hypothermia in patients with hemorrhagic stroke: a systematic review and meta-analysis. World Neurosurg . 2018;111 doi: 10.1016/j.wneu.2018.01.020.
    1. Aoki Y., Aoshima Y., Atsumi K., et al. Perioperative amino acid infusion for preventing hypothermia and improving clinical outcomes during surgery under general anesthesia. Anesthesia & Analgesia . 2017;125(3):793–802. doi: 10.1213/ane.0000000000002278.
    1. Smibert O. C., Slavin M. A., Teh B., et al. Epidemiology and risks for infection following cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. Supportive Care in Cancer . 2020;28(6):2745–2752. doi: 10.1007/s00520-019-05093-5.
    1. Arslan N. C., Sokmen S., Avkan-Oguz V., et al. Infectious complications after cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. Surgical Infections . 2017;18(2):157–163. doi: 10.1089/sur.2016.102.
    1. Hundal R., Shaffer E. A. Gallbladder cancer: epidemiology and outcome. Clinical epidemiology . 2014;6:99–109. doi: 10.2147/CLEP.S37357.
    1. Mao W., Deng F., Wang D., Gao L., Shi X. Treatment of advanced gallbladder cancer: a SEER‐based study. Cancer Medicine . 2020;9(1):141–150. doi: 10.1002/cam4.2679.
    1. Deng Y. L., Li J. Adjuvant chemotherapy in resectable gallbladder cancer is underutilized despite benefits in node-positive patients. Annals of surgical oncology . 2020;27(Suppl 3):940–941. doi: 10.1245/s10434-020-09167-1.
    1. Yang P., Javle M., Pang F., et al. Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients. Hepatobiliary Surgery and Nutrition . 2019;8(6):604–614. doi: 10.21037/hbsn.2019.04.11.
    1. Zhou N., Cheng W., Peng C., Liu Y., Jiang B. Decreased expression of hsa-miR-372 predicts poor prognosis in patients with gallbladder cancer by affecting chloride intracellular channel 1. Molecular Medicine Reports . 2017;16(5):7848–7854. doi: 10.3892/mmr.2017.7520.
    1. Agarwal A. K., Kalayarasan R., Javed A., Gupta N., Nag H. H. The role of staging laparoscopy in primary gall bladder cancer-an analysis of 409 patients. Annals of Surgery . 2013;258(2):318–323. doi: 10.1097/sla.0b013e318271497e.
    1. Yang Y., Tu Z., Cai H., Hu B., Ye C., Tu J. A predictive nomogram for lymph node metastasis of incidental gallbladder cancer: a SEER population-based study. BMC Cancer . 2020;20(1):p. 828. doi: 10.1186/s12885-020-07341-y.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する